

# Curriculum Vitae

**Date Prepared:** Sep 12, 2022

**Name:** Che-Hung Shen

**Office Address:** National Health Research Institutes  
National Institute of Cancer Research  
No.367, Sheng-Li Rd., North Dist. 704 Tainan, Taiwan

**Work Phone:** (+886) 6-7000123 ext.65115/65161

**Cell Phone:** (+886) 976-720-185

**E-Mail:** chshen@nhri.edu.tw

## **Education:**

2003-2008 Ph.D. Molecular Medicine Institute of Molecular Medicine  
College of Medicine  
National Taiwan University, Taiwan

2001-2003 M.S. Life Science Institute of Life Science  
College of Science and Engineering  
Fu-Jen Catholic University, Taiwan

1996-2000 B.S. Biology Department of Biology  
College of Science and Engineering  
Fu-Jen Catholic University, Taiwan

## **Postdoctoral Training:**

2013-2016 Postdoctoral Fellow Dr. Bin Zheng Cancer Biology  
Cutaneous Biology Research Center  
Massachusetts General Hospital  
Harvard University, USA

2010-2013 Postdoctoral Fellow Dr. Bin Zheng Cancer Biology  
Institute for Cancer Genetics  
Columbia University, USA

2009-2010 Postdoctoral Fellow Dr. Ruey-Hwa Chen Cancer Biology  
Institute of Biological Chemistry  
Academia Sinica, Taiwan

## Faculty Academic Appointment:

2021/09-present	Adjunct Assistant Professor	Ph.D. Program in Tissue Engineering and Regenerative Medicine, National Chung-Hsing University, Taiwan
2017/10-present	Assistant Investigator	National Institute of Cancer Research National Health Research Institutes
2016/08-2017/07	Assistant Research Fellow	Skin Institute China Medical University Hospital

## Last 5-year Publications (\*Corresponding author)

1. Hsieh CC, Hsu SH, Lin CY, Liaw HJ, Li TW, Jiang KY, Chiang NJ, Chen SH, Lin BW, Chen PC, Chan RH, Lin PC, Yeh YM, **Shen CH\*** (2022) CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer. *Br J Cancer* (Accepted) (IF=9.089 )
2. Hsieh, CC., Su YC., Jiang KY., Ito T., Li TW., Kaku-Ito Y., Tsung ST., Chen LT., Hwang DY., **Shen CH\***. (2022) TRPM1 promotes tumor progression in acral melanoma by activating the Ca<sup>2+</sup>/CaMKII $\delta$ /AKT pathway. *Journal of Advanced Research*. DOI: 10.1016/j.jare.2022.03.005 (IF=12.822)
3. Chu Z, Gu L, Hu Y, Zhang X, Li M, Chen J, Teng D, Huang M, **Shen CH**, Cai L, Yoshida T, Qi Y, Niu Z, Feng A, Geng S, Frederick DT, Specht E, Piris A, Sullivan RJ, Flaherty KT, Boland GM, Georgopoulos K, Liu D, Shi Y, Zheng B. (2022) STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming. *Nature Communications*. 13(1):1859. (IF= 17.694)
4. YL Chen, KT Lee, CY Wang, **CH Shen**, SC Chen, WP Chung, YT Hsu, YL Kuo, PS Chen, CH Antonio Cheung, CP Chang, MR Shen, HP Hsu. (2022) Low expression of cytosolic NOTCH1 predicts poor prognosis of breast cancer patients. *American Journal of Cancer Research* 12(5):2084-2101. (IF= 5.942)
5. **Shen, C.H.\***, Hsieh CC, Jiang KY, Lin CY, Chiang NJ, Li TW, Yen CT, Chen WJ, Hwang DY, Chen LT. (2021) AUY922 induces retinal toxicity through attenuating TRPM1. *Journal of Biomedical Science*. 28(1):55. (IF=12.771)
6. Tanaka Y, Murata M, **Shen, C.H.**, Furue M, Ito T. (2021) NECTIN4: A Novel Therapeutic Target for Melanoma. *International Journal of Molecular Sciences* 22(2):976. (IF= 6.208)
7. Ito T, Kaku-Ito Y, Murata M, Furue K, **Shen, C.H.**, Oda Y, Furue M. (2020) Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival. *Journal of Clinical Medicine*. 9(3):690 (IF= 4.964)
8. Hsieh, C. C. and **Shen, C. H\***. (2019) The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma. *Current Treatment Options in Oncology* 20:22. (IF=5.080)

- Casimiro, M. C., Di Sante, G., Di Rocco, A., Loro, E., Pupo, C., Pestell, T., Bisetto, S., Velasco-Velazquez, M. A., Jiao, X., Li, Z., Kusminski, C. M., Seifert, E. L., Wang, C., Ly, D., Zheng, B., **Shen, C. H.**, Scherer, P. E., and Pestell, R. G.\* (2017) Cyclin D1 restrains oncogene-induced autophagy by regulating the AMPK-LKB1 signaling axis. *Cancer research* 77, 3391-3405. (IF=12.701)

## **Other Publications**

- Shen, C. H.**, Kim, S. H., Trousil, S., Frederick, D. T., Piris, A., Yuan, P., Cai, L., Gu, L., Li, M., Lee, J. H., Mitra, D., Fisher, D. E., Sullivan, R. J., Flaherty, K. T., and Zheng, B.\* (2016) Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. *Nature medicine* 22,1056-1061.
- DeRan, M., Yang, J., **Shen, C. H.**, Peters, E. C., Fitamant, J., Chan, P., Hsieh, M., Zhu, S., Asara, J. M., Zheng, B., Bardeesy, N., Liu, J., and Wu, X.\* (2014) Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiotensin-like 1 protein. *Cell reports* 9, 495-503.
- Perez-Lorenzo, R., Gill, K. Z., **Shen, C. H.**, Zhao, F. X., Zheng, B., Schulze, H. J., Silvers, D. N., Brunner, G., and Horst, B. A.\* (2014) A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms. *The Journal of investigative dermatology* 134, 1359-1368.
- Shen, C. H.**, Yuan, P., Perez-Lorenzo, R., Zhang, Y., Lee, S. X., Ou, Y., Asara, J. M., Cantley, L. C., and Zheng, B.\* (2013) Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. *Molecular cell* 52, 161-172.
- Yuan, P., Ito, K., Perez-Lorenzo, R., Del Guzzo, C., Lee, J. H., **Shen, C. H.**, Bosenberg, M. W., McMahon, M., Cantley, L. C., and Zheng, B.\* (2013) Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. *Proceedings of the National Academy of Sciences of the United States of America* 110, 18226-18231.
- Wu, N., Zheng, B., Shaywitz, A., Dagon, Y., Tower, C., Bellinger, G., **Shen, C. H.**, Wen, J., Asara, J., McGraw, T. E., Kahn, B. B., and Cantley, L. C.\* (2013) AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. *Molecular cell* 49, 1167-1175.
- Shen, C. H.**, Chen, H. Y., Lin, M. S., Li, F. Y., Chang, C. C., Kuo, M. L., Settleman, J., and Chen, R. H.\* (2008) Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion. *Cancer research* 68, 7779-7787.
- Wang, W. J., Kuo, J. C., Ku, W., Lee, Y. R., Lin, F. C., Chang, Y. L., Lin, Y. M., Chen, C. H., Huang, Y. P., Chiang, M. J., Yeh, S. W., Wu, P. R., **Shen, C. H.**, Wu, C. T., and Chen, R. H.\* (2007) The tumor suppressor DAPK is reciprocally regulated by tyrosine kinase Src and phosphatase LAR. *Molecular cell* 27, 701-716.

18. **Shen, C. H.**, Chiang, Y. C., Hsu, C. H., and Yang, M. K.\* (2007) Identification and characterization of two *uvrA* genes of *Xanthomonas axonopodis* pathovar citri. *Mol Genet Genomics* 277, 149-160.
19. Yang, M. K.\* , Lin, Y. C., and **Shen, C. H.** (2006) Identification of two gene loci involved in poly-beta-hydroxybutyrate production in *Rhodobacter sphaeroides* FJ1. *J Microbiol Immunol Infect* 39, 18-27.
20. Chen, H. Y., **Shen, C. H.**, Tsai, Y. T., Lin, F. C., Huang, Y. P., and Chen, R. H.\* (2004) Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. *Molecular and cellular biology* 24, 10558-10572.